ArticleJournal of cellular and molecular medicine2020
Diagnostic potential of circulating cell-free microRNAs for community-acquired pneumonia and pneumonia-related sepsis.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Clinical Significance of Transfer RNAs Present in Extracellular Vesicles.International journal of molecular sciences · 2022Pooled it
- Extracellular-Vesicle-Associated Nucleic Acids in the Diagnosis and Treatment of Respiratory Diseases: A Narrative Review.Pharmaceutics · 2026Review
- MiR-100-5p is involved in severe pneumonia in children by targeting MTOR.BMC immunology · 2026Article
- MicroRNA Profiling as a Novel Tool in the Diagnostics of Late-Onset Neonatal Sepsis: A Scoping Review.Children (Basel, Switzerland) · 2025Review
- Study on the diagnostic role of exosome-derived miRNAs in postoperative septic shock and non-septic shock patients.Critical care (London, England) · 2025Article
- Diagnostic value of miR-193a-5p in severe pneumonia and its correlation with prognosis.Journal of cardiothoracic surgery · 2025Article
- Article
- Extracellular vesicles and preterm infant diseases.Frontiers in pediatrics · 2025Review
- Exosomal mediators in sepsis and inflammatory organ injury: unraveling the role of exosomes in intercellular crosstalk and organ dysfunction.Military Medical Research · 2024Review
- Harnessing Extracellular microRNAs for Diagnostics and Therapeutics in Acute Systemic Inflammation.Cells · 2024Review
- MicroRNA Profiles in Critically Ill Patients.Current medicinal chemistry · 2024Review
- Pathologic function and therapeutic potential of extracellular vesicle miRNA in sepsis.Frontiers in pharmacology · 2024Review
- Potential of extracellular vesicles for early prediction of severity and potential risk stratification in critical inflammatory diseases.Journal of cell communication and signaling · 2023Review
- A Systematic Review of Gene Expression Studies in Critically Ill Patients with Sepsis and Community-Acquired Pneumonia.Biomedicines · 2023Review
- Article
- Bioengineered extracellular vesicles: future of precision medicine for sepsis.Intensive care medicine experimental · 2023Review
- Extensive blood transcriptome analysis reveals cellular signaling networks activated by circulating glycocalyx components reflecting vascular injury in COVID-19.Frontiers in immunology · 2023Article
- How Extracellular Nano-Vesicles Can Play a Role in Sepsis? An Evidence-Based Review of the Literature.International journal of nanomedicine · 2023Review
- Extracellular Vesicles in Sepsis: Pathogenic Roles, Organ Damage, and Therapeutic Implications.International journal of medical sciences · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free microRNAs (miRNAs) are transferred in disease state including inflammatory lung diseases and are often packed into extracellular vesicles (EVs). To assess their suitability as biomarkers for community-acquired pneumonia (CAP) and severe secondary complications such as sepsis, we studied patients with CAP (n = 30), sepsis (n = 65) and healthy volunteers (n = 47) subdivided into a training (n = 67) and a validation (n = 75) cohort. After precipitating crude EVs from sera, associated small RNA was profiled by next-generation sequencing (NGS) and evaluated in multivariate analyses. A subset of the thereby identified biomarker candidates was validated both technically and additionally by reverse transcription quantitative real-time PCR (RT-qPCR). Differential gene expression (DGE) analysis revealed 29 differentially expressed miRNAs in CAP patients when compared to volunteers, and 25 miRNAs in patients with CAP, compared to those with sepsis. Sparse partial-least discriminant analysis separated groups based on 12 miRNAs. Three miRNAs proved as a significant biomarker signature. While expression levels of miR-1246 showed significant changes with an increase in overall disease severity from volunteers to CAP and to sepsis, miR-193a-5p and miR-542-3p differentiated patients with an infectious disease (CAP or sepsis) from volunteers. Cell-free miRNAs are potentially novel biomarkers for CAP and may help to identify patients at risk for progress to sepsis, facilitating early intervention and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.